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Abstract
Overdiagnosis (and overtreatment) of cancers not bound to become symptomatic during lifetime
is an unavoidable drawback of mammography screening. The magnitude of overdiagnosis has been
estimated to be in the range of 5-10%, and thus acceptable in view of screening benefits as to
reduced mortality. In a recent research article in BMC Women's Health, Jørgensen, Zahl and
Gøtzsche suggest that overdiagnosis may be as high as 33%, based on their analysis of breast cancer
incidence in screened and non-screened areas in Denmark. Here we consider how reliable such
analyses can be, why it might have been useful to adjust comparisons between screened and non-
screened areas for early detection lead time, and what further evidence might be needed to build
on or confirm these results.
Commentary
In the accompanying article Jørgensen, Zahl and Gøtzsche
claim that overdiagnosis generated by screening is as high
as 33%, based on an analysis of breast cancer incidence in
Danish regions covered and uncovered by population
based mammography screening. This is not the first report
of a high overdiagnosis level attributed to mammography
screening by the authors, who have claimed even higher
levels in other countries [1]. Essentially because of over-
diagnosis, definitely a negative aspect of screening, the
authors suggest that mammography screening might do
more harm than good. Such a statement sounds revolu-
tionary in an European scenario where the role of screen-
ing efficacy in reducing mortality has long been
demonstrated by a number of randomized studies and
their meta-analyses. The magnitude of the reported reduc-
tions in mortality (about 30-40% in screened vs. non-
screened in the 50-69 years age range) has justified a
strong recommendation by the European Community [2]
that population based screening by biennial mammogra-
phy should be implemented throughout the Community
territory. Such a process has been initiated in all EC coun-
tries and full coverage with a homogeneous protocol has
already been achieved in many of these countries (e.g. UK,
NL, S, FIN).
That overdiagnosis is a necessary and unavoidable draw-
back of any screening policy for the early detection of can-
cer, nobody can deny. Of course the magnitude of
overdiagnosis depends on several variables, such as indo-
lent, not aggressive cancer prevalence at the screened can-
cer site, screening test detection lead time, screening
aggressiveness, and life expectancy related to screening
age.
That overdiagnosis would be a major problem could be
easily predicted with prostate cancer screening, as all the
favouring conditions for overdiagnosis were present.
Autopsy studies showed a prevalence of prostate cancer
ranging from 30 to 80% in men dying from other causes
[3]. Average detection lead time has been estimated to be
in the range of 10-12 years [4]. PSA, the screening test, is
positive in 12-15% of healthy screened subjects and
prompts random multiple biopsy of the whole prostate
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[5]. The average screening age is 65, accounting for an
average further life expectancy of 15 years (Italy). Over-
diagnosis has been estimated to be 50% or higher,
depending on screening aggressiveness [4,6]. As any urol-
ogist knows, even in absence of an efficient population
based screening policy, poorly efficient spontaneous,
opportunistic screening caused an unsurprising true epi-
demic of prostate cancer throughout the western world. In
the USA incidence more than doubled and peaked in
1992, with a similar trend observed in Australia and in
other western countries. In Florence spontaneous PSA use
was not common before 1990 and compliance to PSA
driven biopsy was as low as 15-20% [7]. Despite this, the
standardized (Europe) incidence rate of prostate cancer
(age 55+) in Florence increased from 97.9 in 1985 to
297.9 in 2005 (+204%), with an increasing trend since
1990 [Tuscany Cancer Registry: http://
www.ispo.toscana.it/rtrt/statistiche/sede.html, last
accessed as of 2009-11-15].
Breast cancer is a different story. Autopsy studies [8] show
a much lower prevalence of invasive and in situ cancer
(1.3% and 8.9%, respectively). Average detection lead
time has been estimated to be in the range of 2-3 years
[9,10]. The rate of breast biopsies (core-biopsy or surgical)
prompted by screening is at most 2-3% [11]. The average
screening age is 60, and average further life expectancy
exceeds 20 years (Italy). Since screening was introduced
no epidemic similar to that seen for prostate cancer has
been seen for breast cancer, although a major shift in stage
occurred. Overdiagnosis has been estimated to be of
much lesser magnitude than suggested by Jørgensen and
colleagues, based on data from efficacy trials (Gothenburg
and Two Counties = 1% [12]; NBSS I (Canada) = 14%
[13]; NBSS II = 11% [13]; Edinburgh = 13% [13]) and
from screening services (Florence = 0-13% [14,15]). The
limited magnitude of such a negative effect of screening
was never considered to outweigh its benefits. In Florence,
where population based screening was implemented in
1990, the standardized (Europe) incidence rate of breast
cancer (age 50-69) rose from 178.2 in 1985 to 279.0 in
2005 (+56%), with a substantially stable trend [Tuscany
Cancer Registry]. A similar trend, with peaks at screening
rounds, was observed in most western countries after a
national policy was implemented.
The best way to estimate overdiagnosis is to look at cancer
incidence before and after screening. According to an ideal
model, screening should start and then stop: a peak of
incidence due to screen detection will be followed by a
drop, possibly below the expected underlying incidence in
absence of screening (adjusted by pre-screening trend).
Overdiagnosis should be estimated after sufficient time
has elapsed since screening stopped, to allow for lead time
effect (2-3 years) to subside. When no overdiagnosis is
present, excess incidence following screening onset
should be fully compensated by the incidence drop fol-
lowing the stopping of screening. The higher the overdiag-
nosis, the higher the incidence peak at screening onset,
the deeper the post-screening drop in incidence. However,
this is what occurs in an ideal model, which is likely not
the case with the scenario studied by Jørgensen and col-
leagues. In fact screening did not stop in the screened
areas (either the official programme or spontaneous
screening), and screening detected (anticipated or over-
diagnosed) cancers continued to be added to the observed
incidence figures. This has probably also occurred beyond
the age of 70: even if screening invitations stop at 69, reg-
ular responders until that age are likely to continue their
mammography controls. Not adjusting for lead time
would lead to overestimating overdiagnosis. It is worth
noting that in the study by Jørgensen and colleagues,
where a late drop of incidence occurred (for example, as
in Funen) suggesting that 70-79 year olds in that area did
actually stop having mammography, overdiagnosis esti-
mate dropped to 19%. This may add evidence to the prin-
ciple that overdiagnosis estimates should be adjusted by
lead time. It would be interesting to know what the mam-
mography use was in 70-79 year olds in both Funen and
also in Copenhagen where no late drop of incidence was
seen, but such data was not available.
Geographic comparisons are tricky. The baseline assump-
tion which makes geographic comparisons reliable is that
compared areas are identical as to variables associated to
the study outcome, that is the incidence. Again, it is
unclear that this is the case with the scenario studied by
Jørgensen and colleagues. Apart from the statement by the
authors that "Danish population is one of the most
homogeneous in the world", reassuring statistical figures
(e.g. education, census, parity habits, proportion of urban
and rural areas) are not provided, and having the "second
largest city" and "rural areas" does not necessarily equate
to non-screened and screened areas. Baseline pre-screen-
ing (1971-1990) incidence is similar, being only 8%
higher in screened as compared to non-screened areas
(screening age core group). After 1991 incidence increases
substantially in non-screened areas (+44% as compared to
1971-1990). We don't know how much of this is due to
opportunistic screening (no data on mammography use
are provided) or to causes other than opportunistic
screening (e.g. hormone replacement therapy (HRT),
changes in lifestyle or reproductive habits, usually occur-
ring one or two decades before). Due to the masking effect
of screening, we ignore what would have been the sponta-
neous trend in incidence in screened areas, and we can not
be sure that it would be the same as in non-screened areas.
Indeed, had causes other than screening (e.g. HRT use,
changes in lifestyle or reproductive habits) been more
prevalent in the screened areas, this would cause a higher,Publish with BioMed Central    and   every 
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screening unrelated underlying incidence and would also
lead to overdiagnosis overestimation.
In summary, the evidence provided by Jørgensen and col-
leagues is not yet fully convincing. It does not adjust for
lead time, which tends to overestimate overdiagnosis. It is
also based on the assumption that considered screened
and non-screened areas are comparable as to underlying
incidence, whereas no detailed supporting evidence of
their comparability (e.g. risk factors) is provided to sup-
port their case. The authors' challenge to the European
Community recommendation of implementing popula-
tion-based mammography screening, and their message
that screening might do "more harm than good" could be
considered to be based on some unproven assumptions.
The "good" is well established by randomized trials and
population screening outcomes. Some of the "harm" is
unavoidable with screening and overdiagnosis is part of
that, but the message that the magnitude of such "harm"
may counterbalance the "good" is not yet confirmed and
is countered by several other studies on overdiagnosis
which give estimates between 0 and 13% [11-14].
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